GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cellectis S.A.
Cellectis is a French biotech company, a pioneer in gene editing (TALEN) and allogeneic CAR-T therapy. Its stock price reflects both its significant scientific potential and the high risks and long clinical development pipeline.
Share prices of companies in the market segment - Oncology cell gene therapy
Cellectis is a French biotech company, a pioneer in gene editing (CAR-T) for the creation of universal immunotherapeutic drugs against cancer. We've categorized it under "Oncology: Cell Therapy." The chart below shows the dynamics of this breakthrough biotech sector.
Broad Market Index - GURU.Markets
Cellectis is a French biotech company, a pioneer in gene editing (CAR-T) for the development of universal immunotherapeutic drugs against cancer. It is a component of the GURU.Markets index. The chart below shows the US market. See how Cellectis shares compare to the US market trend.
Change in the price of a company, segment, and market as a whole per day
CLLS - Daily change in the company's share price Cellectis S.A.
For Cellectis, a gene editing company, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials and technological breakthroughs. This metric forms the basis for analyzing biotech platforms on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Cellectis S.A. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the performance of CLLS, a gene editing pioneer, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cellectis is a French biopharmaceutical company, a pioneer in gene editing. This is one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cellectis S.A.
The year-over-year performance of Cellectis S.A., a pioneer in gene editing, is a story of developing "off-the-shelf" CAR-T cell therapies. Its 12-month market cap depends entirely on clinical trial data. The success of its approach, which uses cells from healthy donors, could make cell therapy more accessible and affordable.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Cellectis S.A. is a French biotechnology company pioneering the development of universal (allogeneic) CAR-T therapy based on gene editing. Its stock price reflects the enormous potential of its scientific platform and the high risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cellectis, a pioneer in gene editing, is a high-risk, high-potential company. Its stock price (ADR) is entirely dependent on clinical trial results. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become the new standard of cancer treatment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cellectis S.A.
The performance of Cellectis, a gene editing company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its innovative, "off-the-shelf" CAR-T therapies for cancer treatment, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Cellectis is a pioneer in genetic engineering, developing CAR-T therapy for cancer treatment. This cell and gene therapy sector is at the forefront of medicine. The chart below reflects investors' confidence in the revolutionary potential of these technologies, as well as their concerns about the high costs and risks of clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cellectis is a French company, a pioneer in the field of genetic engineering (CAR-T therapy). Its shares are a bet on a scientific revolution in cancer treatment. Their performance is driven by news from laboratories and clinics, rather than by general market trends, which is typical for fundamentally innovative companies.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cellectis S.A.
Shares of Cellectis, a French pioneer in genome editing and CAR-T therapy, are extremely volatile. Weekly price movements depend entirely on the results of clinical trials of their allogeneic ("off-the-shelf") cell products. The chart below illustrates how short-term scientific events shape value in cutting-edge biotech.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
How unique is Cellectis's performance in the biotech sector? This chart compares the gene editing pioneer's weekly stock price movements with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect the broader sentiment across the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cellectis is a pioneer in genome editing and allogeneic CAR-T therapy. It's a revolutionary but risky technology. This chart compares its volatile weekly performance to the market, showing how its shares move based on news of scientific breakthroughs, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
CLLS - Market capitalization of the company Cellectis S.A.
The Cellectis S.A. market cap chart represents the valuation of one of the pioneers in gene editing. This French biotech company's market capitalization depends on the success of its TALEN platform and developments in off-the-shelf CAR-T therapy. The dynamics illustrate the risks and promises associated with advanced genetic engineering.
CLLS - Share of the company's market capitalization Cellectis S.A. within the market segment - Oncology cell gene therapy
Cellectis S.A. is a pioneer in gene editing and allogeneic CAR-T therapy. Its market share reflects its fundamental contribution to this field. Its market capitalization is a measure of its technological platform and clinical programs.
Market capitalization of the market segment - Oncology cell gene therapy
The chart below shows the combined market capitalization of gene editing pioneers. Cellectis is one of the pioneers of this revolutionary technology. The dynamics in the chart reflect both the enormous scientific potential and the fierce competition and patent disputes in this field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of one of the pioneers in genome editing. Cellectis S.A.'s market cap reflects the valuation of its TALEN platform for creating "universal" cell therapy. The line shows how fundamental science is competing for its share of the future of cancer and genetic disease treatment.
Book value capitalization of the company, segment and market as a whole
CLLS - Book value capitalization of the company Cellectis S.A.
Cellectis S.A.'s book value is its scientific and production capital. The chart below reflects the valuation of its patents for the TALEN® gene editing platform and its manufacturing capacity for allogeneic CAR-T therapies. Growth in the pipeline reflects investments in the development of "off-the-shelf" cell therapies for cancer treatment.
CLLS - Share of the company's book capitalization Cellectis S.A. within the market segment - Oncology cell gene therapy
Cellectis's tangible assets include its cutting-edge laboratories and manufacturing facilities in Paris and Raleigh for the development and production of "off-the-shelf" gene-editing cell therapies. The chart shows its share of this unique and capital-intensive scientific and manufacturing infrastructure.
Market segment balance sheet capitalization - Oncology cell gene therapy
Below you can see the overall book value of the biotech sector. Compared to this, Cellectis, a pioneer in genome editing, looks like a lightweight. Its capital isn't in its factories, but in some of the most valuable intellectual property in science. Its balance sheet is modest compared to its scientific potential.
Book value of all companies included in the broad market index - GURU.Markets
Cellectis is a pioneer in the fields of genome editing (TALEN) and CAR-T therapy. The company's assets are not drugs, but fundamental patents and a scientific platform. Their balance sheet represents the value of one of the "toolkits" for reprogramming biology, the foundation of the entire real world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cellectis S.A.
Cellectis's balance sheet consists of cash and patents for genome editing technology. Its market capitalization, close to its cash value, shows that investors are tired of waiting for results from one of the industry's pioneers. A chart showing MvsBCap_Co ≈ 1 indicates the company's status as a "scientific archive," not a future leader.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Cellectis is a pioneer in gene editing, developing "universal" (allogeneic) CAR-T cell therapy. Its value lies in its scientific platform. The graph shows a high speculative estimate of its potential to create more affordable cancer treatment than personalized methods.
Market to book capitalization ratio for the market as a whole
Cellectis is a biotech company pioneering genome editing and developing allogeneic CAR-T (ready-to-use) therapy for cancer treatment. The company's value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for innovative approaches in oncology.
Debts of the company, segment and market as a whole
CLLS - Company debts Cellectis S.A.
Cellectis, a pioneer in gene editing and allogeneic CAR-T therapy, is using debt to finance its revolutionary research. This chart shows how the company is raising capital to conduct clinical trials of its "off-the-shelf" cell therapies. In this field, debt is a bet on creating more accessible cancer treatments.
Market segment debts - Oncology cell gene therapy
Cellectis is a French biotech company, a pioneer in gene editing and the development of off-the-shelf (allogeneic) CAR-T cell therapy. This is one of the most advanced and complex areas in medicine. This chart shows how the company funds its breakthrough, yet extremely capital-intensive and risky, research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cellectis S.A.
Cellectis is a pioneer in gene editing and allogeneic CAR-T cell therapy. This chart shows its reliance on external capital to fund its breakthrough, yet extremely expensive, research. For a biotech company at the forefront of science, debt is a huge risk that can only pay off if it successfully brings its products to market.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Cellectis is a French biotech company, a pioneer in the field of genome editing (TALEN) and the development of allogeneic CAR-T therapy. This is cutting-edge science, but it is also very expensive. The chart shows how the company's debt load for R&D funding compares to the market capitalization of the entire cell therapy sector.
Debt to book value of all companies in the market
Cellectis (CLLS) is a biotech company pioneering genome editing and developing allogeneic CAR-T cell therapy. This cutting-edge research is capital-intensive. This chart shows the overall level of debt in the economy. It clearly demonstrates why companies like Cellectis are financed with equity rather than debt.
P/E of the company, segment and market as a whole
P/E - Cellectis S.A.
This metric for Cellectis, a pioneer in genome editing, is a measure of faith in its scientific approach. There is no P/E ratio. The company's valuation is based on the potential of its technology to create "off-the-shelf" CAR-T cell therapies, but it faces intense competition and difficulties in clinical trials.
P/E of the market segment - Oncology cell gene therapy
This chart shows the average P/E ratio for biotech companies. For Cellectis, a pioneer in genome editing, it serves as a backdrop. It reflects the overall level of investor confidence in this technology, providing context for Cellectis's valuation, which is a bet on its unique scientific approach.
P/E of the market as a whole
Cellectis is a French biotech company, a pioneer in genome editing and allogeneic CAR-T therapy. The company develops "off-the-shelf" cell therapies for cancer treatment. This risk appetite chart helps understand how investors value companies at the forefront of genetic engineering.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cellectis S.A.
Cellectis is a French biotech company, a pioneer in gene editing and the developer of allogeneic (universal) CAR-T therapy for cancer treatment. This schedule reflects expectations for its cutting-edge scientific platform. The assessment depends on the results of clinical trials and the ability to create "ready-to-use" cell therapies.
%20P%2FE%20Cellectis%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cellectis-S.A.&v=1772561423137 "Chart of the company's future (projected) P/E Cellectis S.A.")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Cellectis is a French biotech company pioneering gene editing and developing allogeneic CAR-T therapy. This chart reflects the company's long-term profitability expectations. It demonstrates how highly the market values their cutting-edge scientific platform and potential for creating "off-the-shelf" cell therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772561423180 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Cellectis is a French biotech company, a pioneer in gene editing and allogeneic CAR-T therapy. Its future depends on the success of its scientific platform. This market expectations chart reflects investor willingness to fund high-risk, fundamental research with the potential for significant impact on medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772561423236 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cellectis S.A.
Cellectis is a French biotech company, a pioneer in the field of genome editing. It is developing a "universal" CAR-T cell therapy using its TALEN technology. Its financial performance reflects significant investments in the development of next-generation cancer drugs.
Profit of companies in the market segment - Oncology cell gene therapy
Cellectis is a pioneer in gene editing, developing off-the-shelf CAR-T therapies for cancer. The company is at the forefront of science, but also at the forefront of risk. This biotech chart reflects the enormous investment in platform technologies, where a single successful product can recoup years of research and change the standard of oncology treatment.
Overall market profit
Cellectis is a pioneer in gene editing, developing allogeneic CAR-T therapy ("ready-to-use"). Its future depends on the success of clinical trials and the safety of its technology. This is a high-risk biotech venture, unrelated to the macroeconomic trends that shape this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cellectis S.A.
Cellectis is a pioneer in gene editing, developing allogeneic CAR-T therapy (using donor cells) for cancer treatment. This timeline reflects expectations, which are entirely dependent on the success of its clinical programs. The potential to create "off-the-shelf" cell therapies is a key factor in these projections.
%20profit%20of%20the%20company%20Cellectis%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cellectis-S.A.&v=1772561423452 "Graph of future (projected) profit of the company Cellectis S.A.")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Cellectis is a French biotechnology company pioneering gene editing and developing allogeneic CAR-T therapy. This chart shows the revenue forecast for the cell and gene therapy sector. It reflects expectations for breakthroughs in cancer treatment. This backdrop is important for assessing the potential of Cellectis's cutting-edge gene editing technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772561423490 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Cellectis is a pioneer in gene editing, developing allogeneic CAR-T therapy. Its future depends on scientific breakthroughs and investment. The economic backdrop shown here influences investor risk appetite and the availability of capital to fund breakthrough, but very expensive, medical research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772561423502 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cellectis S.A.
Cellectis is a French biotech company, a pioneer in genome editing and CAR-T cell therapy. It develops "off-the-shelf" (allogeneic) cell therapies for cancer treatment. This chart shows how investors value its cutting-edge scientific platform, which could make cell therapy more accessible.
P/S market segment - Oncology cell gene therapy
Cellectis is a French biotech company pioneering gene editing and developing allogeneic CAR-T cell therapy. Its TALEN technology enables the creation of ready-to-use drugs from donor cells for cancer treatment. This chart shows the average valuation in the sector, helping to understand the market premium placed on this cutting-edge scientific platform.
P/S of the market as a whole
Cellectis is a French biotech company, a pioneer in gene editing and the development of allogeneic CAR-T cancer therapy. TALEN technology enables the creation of "ready-to-use" cell products from healthy donors. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cellectis S.A.
Cellectis is a pioneer in gene editing and CAR-T therapy. Currently in the clinical stage, it is evaluated based on its future potential. This chart reflects investor expectations that its technologies will lead to breakthrough cancer treatments.
%20P%2FS%20Cellectis%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cellectis-S.A.&v=1772561423681 "The graph of the company's future (projected) P/S Cellectis S.A.")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Cellectis is a French biopharmaceutical company pioneering gene editing and allogeneic CAR-T cell therapy. This chart compares market expectations for its future revenue with other oncology companies. This valuation reflects investor confidence in its cutting-edge TALEN technology platform.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772561423694 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Cellectis is a pioneer in gene editing, developing "off-the-shelf" (allogeneic) CAR-T cell therapies. It is betting on a revolution in cancer treatment. Market optimism, as reflected in this chart, is vital for the company, as it provides access to the massive investment needed to advance this complex technology through clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772561423697 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cellectis S.A.
Cellectis is a French biotech company pioneering gene editing and developing off-the-shelf (allogeneic) CAR-T therapy. Currently in the clinical stage, its revenue comes from upfront and milestone payments from major pharmaceutical partners. The chart reflects funding supporting its cutting-edge oncology research.
Sales of companies in the market segment - Oncology cell gene therapy
Cellectis is a French biotech company pioneering gene editing and allogeneic CAR-T therapy. Its technology enables the creation of universal T cells from healthy donors for cancer treatment. Currently, revenue is generated from partnerships. This graph demonstrates the enormous potential of "off-the-shelf" cell therapy, which could make treatment more accessible.
Overall market sales
Cellectis is a pioneer in gene editing, developing allogeneic CAR-T cell therapies. The company's prospects depend entirely on the success of its clinical research. The economic situation, reflected in the chart, impacts the availability of capital, which is critical for funding long-term biotech research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cellectis S.A.
Cellectis is a French biotech company, a pioneer in genome editing and allogeneic CAR-T therapy. It develops "ready-to-use" cell therapies for cancer from donor cells. This chart reflects analysts' confidence in Cellectis' technology platform and its potential to create breakthrough treatments.
%20sales%20of%20the%20company%20Cellectis%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cellectis-S.A.&v=1772561423756 "Schedule of future (projected) sales of the company Cellectis S.A.")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Cellectis is a French biotech company, a pioneer in genome editing and developer of off-the-shelf (allogeneic) CAR-T therapy. This chart shows general forecasts for the cell therapy sector, allowing one to assess how the company's cutting-edge technology and its clinical developments may impact the future of cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772561423767 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Cellectis S.A. is a French biotech company, a pioneer in gene editing and allogeneic CAR-T therapy. This chart, reflecting the investment climate in biotech, is critically important. Developing such advanced platforms requires enormous capital, and the availability of funding is directly dependent on overall economic sentiment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772561423886 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cellectis S.A.
Cellectis is a biotechnology company pioneering gene editing and developing allogeneic CAR-T cells for cancer treatment. Its goal is to create "off-the-shelf" cell therapies. This schedule reflects the significant investments in research and manufacturing required to realize this ambitious goal in immuno-oncology.
Market segment marginality - Oncology cell gene therapy
Cellectis S.A. is one of the pioneers in gene editing (TALEN®) and CAR-T therapy. They develop allogeneic ("off-the-shelf") cell therapies. This graph reflects their long-standing and deep investment in science, which forms the basis for the creation of a new generation of cancer drugs.
Market marginality as a whole
Cellectis is a French biotech company, a pioneer in gene editing and the development of allogeneic CAR-T therapy. The overall picture of profitability is irrelevant to them. Their value lies in their cutting-edge scientific platform. Success depends on the results of clinical trials and the ability to create "off-the-shelf" cell-based cancer therapies.
Employees in the company, segment and market as a whole
Number of employees in the company Cellectis S.A.
Cellectis is a French biotech company, a pioneer in gene editing (TALEN) and allogeneic CAR-T therapy. This graph shows its large team of scientists. The scale of its staff reflects the complexity and capital intensity of its scientific platform and clinical development.
Share of the company's employees Cellectis S.A. within the market segment - Oncology cell gene therapy
Cellectis is a pioneer in gene editing, developing allogeneic CAR-T cell therapies based on its TALEN technology. This chart shows the percentage of leading scientists in the field of gene editing that the company attracts. It illustrates its role as a leader in the development of universal anti-cancer cell therapies.
Number of employees in the market segment - Oncology cell gene therapy
Cellectis S.A. is a French biotechnology company pioneering genome editing and developing allogeneic CAR-T therapy. This chart shows employment in this cutting-edge biotech field. The growing number of scientists reflects progress in developing a platform for creating "universal" cells for cancer treatment, a key goal in cell therapy.
Number of employees in the market as a whole
Cellectis S.A. is a French biotechnology company pioneering genome editing and developing allogeneic CAR-T therapy (using donor cells) for cancer treatment. In this graph showing the overall labor market, companies like Cellectis represent the vanguard of global science, creating jobs for elite researchers in the field of genetic engineering.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cellectis S.A. (CLLS)
Cellectis S.A. is a French biotech company pioneering genome editing and CAR-T therapy. Its value lies in the potential of its revolutionary technology. This chart clearly demonstrates a business driven by intellectual capital, with an extremely high market capitalization per employee. Investors are betting on their scientific breakthroughs.
%20of%20the%20company%20Cellectis%20S.A.%20(CLLS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cellectis-S.A.-CLLS&v=1772561424104 "Chart of market capitalization per employee (in thousands of dollars) of the company Cellectis S.A. (CLLS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Cellectis is a pioneer in gene editing, developing allogeneic CAR-T therapy ("universal") for cancer treatment. Its TALEN technology is an alternative to CRISPR. The chart shows the significant premium the market commands for its scientific platform. The per-employee cost reflects investors' faith in the team's ability to create the cure of the future.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772561424129 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Cellectis is a pioneer in gene editing, having developed TALEN technology. The company uses it to create allogeneic ("off-the-shelf") CAR-T cell therapies. This graph shows a very high market value per employee, reflecting the fundamental value of their scientific platform for the future of oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772561424141 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cellectis S.A. (CLLS)
Cellectis (CLLS) is a French biotech company, a pioneer in genome editing (TALEN) and the development of "allogeneic" (universal) CAR-T cells. It has extensive R&D. This chart shows the high "cost" of this science—the negative profit (expense) per scientist.
%20Chart%20Cellectis%20S.A.%20(CLLS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cellectis-S.A.-CLLS&v=1772561424171 "Company Profit Per Employee (in thousands of dollars) Chart Cellectis S.A. (CLLS)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Cellectis S.A. is a French biotech company, a pioneer in the field of genome editing (TALEN) and allogeneic CAR-T therapy. Their goal is to create universal cell-based therapies against cancer. This chart demonstrates the benchmark for biotech staff efficiency. It is important for assessing how effectively Cellectis' scientific team is using its platform.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772561424176 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Cellectis S.A. is a French biotech company, a pioneer in gene editing (using TALEN technology) and the development of "universal" (allogeneic) CAR-T cells. This company has extensive R&D. The graph shows the high cost of research (negative profit) per scientist in the effort to create "off-the-shelf" cell therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772561424231 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cellectis S.A. (CLLS)
Cellectis is a pioneer in gene editing, developing allogeneic (donor-derived) CAR-T therapy. This chart reflects its scientific focus. Zero revenue per employee is the norm for a company whose complex and potentially revolutionary technology is in clinical trials and requires massive investments in R&D.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cellectis-S.A.-CLLS&v=1772561424236 "Sales chart per company employee Cellectis S.A. (CLLS)")
Sales per employee in the market segment - Oncology cell gene therapy
Cellectis (CLLS) is a French biotech company, a pioneer in gene editing (TALEN®) and the development of allogeneic CAR-T cells (UCART) for cancer treatment. This chart shows the revenue (from partnerships) generated by each employee (scientist). It's an indicator of the productivity of their cutting-edge R&D platform.
Sales per employee for the market as a whole
Cellectis S.A. is a French biotech company, a pioneer in gene editing (TALEN) and allogeneic CAR-T therapy (CAR-T cells). It is a clinical-stage R&D company with no stable revenue. This graph (close to zero) reflects investment in research: a team of scientists is working on a platform that, if successful, could transform cancer treatment.
Short shares by company, segment and market as a whole
Shares shorted by company Cellectis S.A. (CLLS)
Cellectis S.A. is a French biotech pioneer in genome editing (TALEN) and allogeneic (donor) CAR-T therapy. This chart shows bearish bets. The shorts are driven by high risks: the technology is complex, the company has experienced trial halts due to side effects, and is lagging behind competitors in the CAR-T race.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cellectis-S.A.-CLLS&v=1772561424323 "Short Shares Chart for the Company Cellectis S.A. (CLLS)")
Shares shorted by market segment - Oncology cell gene therapy
Cellectis (CLLS) is a French biotech company, a pioneer in gene editing (TALEN) and the development of allogeneic (donor-derived) CAR-T therapy. This chart shows the odds against the entire biotech sector. The rising odds against the industry reflect investor skepticism about the success of this complex technology and a lack of funding.
Shares shorted by the overall market
Cellectis is a pioneer in gene editing for oncology. This is a long-term, high-risk science. When the market is dominated by widespread pessimism (as in this chart), the appetite for funding capital-intensive, revenue-depleted biotechs evaporates. Investors are risk-averse, and companies like Cellectis struggle to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cellectis S.A. (CLLS)
Cellectis is a pioneer in gene editing (TALEN). The stock is highly speculative and dependent on R&D. This chart can soar above 70 on positive trial data or partnerships. Oversold territory (<30) often reflects setbacks, delays, or funding concerns during the "venture winter."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cellectis-S.A.-CLLS&v=1772561424385 "RSI 14 indicator chart for the company's stock Cellectis S.A. (CLLS)")
RSI 14 Market Segment - Oncology cell gene therapy
Cellectis is a pioneer in the field of gene-engineered cell lines (TALENs). The company develops "allogeneic" (universal) CAR-T therapies using healthy donor cells to treat cancer. This chart shows the overall "temperature" in the volatile gene and cell therapy sector. It helps separate the dynamics of CLLS from the general "hype" or "disappointment" in this complex field.
RSI 14 for the overall market
Cellectis (CLLS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLLS (Cellectis S.A.)
Cellectis is a French biopharmaceutical company and a pioneer in gene editing (TALEN). It is developing "allogeneic" CAR-T therapies (from a healthy donor), which should reduce the cost of cancer treatment. This chart shows the speculative average price target from analysts based on their confidence in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLLS-Cellectis-S.A.&v=1772561424455 "A chart showing analyst consensus forecasts for the expected stock price. CLLS (Cellectis S.A.)")
The difference between the consensus estimate and the actual stock price CLLS (Cellectis S.A.)
Cellectis (CLLS) is a French biotech pioneer in genetic engineering. The company develops allogeneic (universal, off-the-shelf) CAR-T therapies using its unique editing technology (TALEN). This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in this futuristic R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLLS-Cellectis-S.A.&v=1772561424465 "A chart showing the difference between the consensus forecast and the actual stock price. CLLS (Cellectis S.A.)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Cellectis is a French pioneer in gene editing (TALEN). The company develops "universal" (allogeneic) CAR-T cells that don't need to be individually created for each patient. This chart shows general expectations for the cell therapy sector. It reflects whether experts believe in the future of "off-the-shelf" cell therapies or consider them too complex.
Analysts' consensus forecast for the overall market share price
Cellectis is a biotech at the cutting edge of science (genome editing, CAR-T). It's a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = "risk aversion," and capital for R&D (like CLLS) dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cellectis S.A.
Cellectis (CLLS) is a Paris-based biotech company, a pioneer in gene editing. They specialize in allogeneic (off-the-shelf) CAR-T therapy—the creation of universal cancer-killing cells. This graph is a pure R&D bet. Its valuation reflects the market's faith in their (very early) scientific platform and their ability to compete with autologous (personal) CAR-T.
AKIMA Market Segment Index - Oncology cell gene therapy
Cellectis is a French biotech company, a pioneer in genome editing (TALEN) and allogeneic CAR-T therapy (cell-ready therapy for cancer). This chart shows the average index for the cell therapy sector. It provides investors with a benchmark for how Cellectis, with its breakthrough but risky technology, compares to the sector average.
The AKIM Index for the overall market
Cellectis is a biotech company pioneering the field of genome editing (TALEN) for the creation of allogeneic (universal) CAR-T cell therapies. This chart, reflecting the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to funding this cutting-edge scientific platform.
